Early complement activation increases in the brain in some aged normal subjects

被引:16
作者
Loeffler, DA [1 ]
Camp, DM
Schonberger, MB
Singer, DJ
LeWitt, PA
机构
[1] William Beaumont Hosp, Res Inst, Div Neurol, Royal Oak, MI 48073 USA
[2] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA
[3] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA
关键词
aging; Alzheimer's disease; brain; complement activation; ELISA; inflammation;
D O I
10.1016/j.neurobiolaging.2003.11.003
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Complement activation is increased in Alzheimer's disease (AD) and may contribute to the development and progression of this disorder. To compare early complement activation between normal and AD brain specimens, C4d and iC3b concentrations were measured in hippocampus, entorhinal cortex, temporal cortex, parietal cortex, and cerebellum from aged normal and AD subjects (n = 10-14 for both), and in hippocarnpus and entorhinal cortex from younger normal subjects (n = 5-6). C4d and iC3b levels increased 2.3- to 4.6-fold in AD versus aged normal specimens (all P < 0.05), with lowest concentrations of these activation proteins generally in cerebellum. No significant differences were present between aged and younger normal C4d and iC3b levels in hippocampus or entorhinal cortex. However, the concentrations of these proteins were markedly increased in several aged normal specimens. Normal subject age was moderately associated with both C4d (r = 0.49) and iC3b (r = 0.53) concentrations in the hippocampus. Increased brain complement activation in some elderly individuals may promote the subsequent development of AD. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:1001 / 1007
页数:7
相关论文
共 73 条
[41]  
Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.3.CO
[42]  
2-U
[43]  
Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO
[44]  
2-X
[45]   Microglia and inflammatory mechanisms in the clearance of amyloid β peptide [J].
Rogers, J ;
Strohmeyer, R ;
Kovelowski, CJ ;
Li, R .
GLIA, 2002, 40 (02) :260-269
[46]   CLINICAL-TRIAL OF INDOMETHACIN IN ALZHEIMERS-DISEASE [J].
ROGERS, J ;
KIRBY, LC ;
HEMPELMAN, SR ;
BERRY, DL ;
MCGEER, PL ;
KASZNIAK, AW ;
ZALINSKI, J ;
COFIELD, M ;
MANSUKHANI, L ;
WILLSON, P ;
KOGAN, F .
NEUROLOGY, 1993, 43 (08) :1609-1611
[47]   COMPLEMENT ACTIVATION BY BETA-AMYLOID IN ALZHEIMER-DISEASE [J].
ROGERS, J ;
COOPER, NR ;
WEBSTER, S ;
SCHULTZ, J ;
MCGEER, PL ;
STYREN, SD ;
CIVIN, WH ;
BRACHOVA, L ;
BRADT, B ;
WARD, P ;
LIEBERBURG, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) :10016-10020
[48]   A double-blind, placebo-controlled trial of diclofenac misoprostol in Alzheimer's disease [J].
Scharf, S ;
Mander, A ;
Ugoni, A ;
Vajda, F ;
Christophidis, N .
NEUROLOGY, 1999, 53 (01) :197-201
[49]   ENHANCED CYTOTOXICITY OF AMYLOID BETA-PEPTIDE BY A COMPLEMENT-DEPENDENT MECHANISM [J].
SCHULTZ, J ;
SCHALLER, J ;
MCKINLEY, M ;
BRADT, B ;
COOPER, N ;
MAY, P ;
ROGERS, J .
NEUROSCIENCE LETTERS, 1994, 175 (1-2) :99-102
[50]   COMPLEMENT-MEDIATED NEUROTOXICITY IS REGULATED BY HOMOLOGOUS RESTRICTION [J].
SHEN, Y ;
HALPERIN, JA ;
LEE, CM .
BRAIN RESEARCH, 1995, 671 (02) :282-292